Naglazyme er indiceret til langvarig enzymsubstitutionsbehandling hos patienter med bekræftet diagnose af Mucopolysaccharidose VI (MPS VI; N- acetylgalactosamine 4- sulfatase mangel).
Naglazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine 4-sulfatase deficiency).